Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
10.1097/JTO.0b013e318220c93e
Saved in:
Main Authors: | Tan, E.-H., Goss, G.D., Salgia, R., Besse, B., Gandara, D.R., Hanna, N.H., Yang, J.C.-H., Thertulien, R., Wertheim, M., Mazieres, J., Hensing, T., Lee, C., Gupta, N., Pradhan, R., Qian, J., Qin, Q., Scappaticci, F.A., Ricker, J.L., Carlson, D.M., Soo, R.A. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Review |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/117354 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
by: Toh, H.C., et al.
Published: (2014) -
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
by: Jasinghe, V.J., et al.
Published: (2011) -
In vitro and in vivo study of ABT-869 in treatment acute myeloid leukemia (AML) alone or in combination with chemotherapy or HDAC inhibitors: insight into molecular mechanism and biologic characterization
by: ZHOU JIANBIAO
Published: (2010) -
Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors
by: Li, Y., et al.
Published: (2014) -
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside
by: Zhou, J., et al.
Published: (2011)